Distinct from conventional GBM, E-GBM frequently harbors BRAF V600E mutations, TERT promoter mutations, and CDKN2A/B homozygous deletions, correlating with aggressive clinical behavior, rapid recurrence, and dismal prognosis (13). The gene discussed is CDKN2A; the disease is glioblastoma.